0713 EMB 7am ET Ji Xing
BioCentury & Getty Images

Emerging Company Profile

Ji Xing: building a CV pipeline for Chinese patients

Emerging Company Profile: Ji Xing to advance CV portfolio with $40M series B and Merck vet at the helm

Armed with a $40 million series B round and 25-year Merck veteran Joseph Romanelli as CEO, Ji Xing plans to advance and grow its China-focused cardiovascular

Read the full 649 word article

How to gain access

Continue reading with a
two-week free trial.